Top

Published in:

03-01-2024 | Pancreatic Cancer | Review

The association between circulating 25-hydroxyvitamin D and pancreatic cancer: a systematic review and meta-analysis of observational studies

Authors: Yajing Shen, Junfen Xia, Chuncheng Yi, Tiandong Li, Peng Wang, Liping Dai, Jianxiang Shi, Keyan Wang, Changqing Sun, Hua Ye

Published in: European Journal of Nutrition | Issue 3/2024

Abstract

Purpose

The relationship between circulating 25-hydroxyvitamin D [25(OH)D] and pancreatic cancer has been well studied but remains unclear. The purpose of this study was to elucidate the association between circulating 25(OH)D and pancreatic cancer by using a meta-analytic approach.

Methods

PubMed, Embase, and Wed of Science databases were searched through October 15, 2022. A random or fixed-effects model was used to estimate the pooled odds ratio (OR), risk ratio (RR), hazard ratio (HR) and their 95% confidence intervals (CIs).

Results

A total of 16 studies including 529,917 participants met the inclusion criteria, of which 10 reported incidence and 6 reported mortality. For the highest versus lowest categories of circulating 25(OH)D, the pooled OR of pancreatic cancer incidence in case–control studies was 0.98 (95% CI 0.69–1.27), and the pooled HRs of pancreatic cancer mortality in cohort and case–control studies were 0.64 (95% CI 0.45–0.82) and 0.78 (95% CI 0.62–0.95), respectively. The leave-one-out sensitivity analyses found no outliers and Galbraith plots indicated no substantial heterogeneity.

Conclusion

Evidence from this meta-analysis suggested that high circulating 25(OH)D levels may be associated with decreased mortality but not incidence of pancreatic cancer. Our findings may provide some clues for the treatment of pancreatic cancer and remind us to be cautious about widespread vitamin D supplementation for the prevention of pancreatic cancer.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763CrossRefPubMed

You L, Lv Z, Li C, Ye W, Zhou Y, Jin J, Han Q (2021) Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019. ESMO Open 6:100255. https://doi.org/10.1016/j.esmoop.2021.100255CrossRefPubMedPubMedCentral

Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267. https://doi.org/10.1371/journal.pmed.1000267CrossRefPubMedPubMedCentral

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A et al (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356–387. https://doi.org/10.1016/j.ejca.2018.07.005CrossRefPubMed

Tempero MA (2019) NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw 17:603–605. https://doi.org/10.6004/jnccn.2019.5007CrossRefPubMed

Clinton SK, Giovannucci EL, Hursting SD (2020) The World Cancer Research Fund/American Institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions. J Nutr 150:663–671. https://doi.org/10.1093/jn/nxz268CrossRefPubMed

Qin X, Chen J, Jia G, Yang Z (2023) Dietary factors and pancreatic cancer risk: an umbrella review of meta-analyses of prospective observational studies. Adv Nutr 14:451–464. https://doi.org/10.1016/j.advnut.2023.02.004CrossRefPubMedPubMedCentral

Zheng W, McLaughlin JK, Gridley G, Bjelke E, Schuman LM, Silverman DT, Wacholder S et al (1993) A cohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control 4:477–482. https://doi.org/10.1007/bf00050867CrossRefPubMed

10.

Peila R, Coday M, Crane TE, Saquib N, Shadyab AH, Tabung FK, Zhang X et al (2022) Healthy lifestyle index and risk of pancreatic cancer in the women’s health initiative. Cancer Causes Control 33:737–747. https://doi.org/10.1007/s10552-022-01558-xCrossRefPubMedPubMedCentral

11.

Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS (2003) Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol 157:1115–1125. https://doi.org/10.1093/aje/kwg098CrossRefPubMed

12.

Chatterjee R, Fuss P, Vickery EM, LeBlanc ES, Sheehan PR, Lewis MR, Dolor RJ et al (2021) Vitamin D supplementation for prevention of cancer: the D2d cancer outcomes (D2dCA) ancillary study. J Clin Endocrinol Metab 106:2767–2778. https://doi.org/10.1210/clinem/dgab153CrossRefPubMedPubMedCentral

13.

Haykal T, Samji V, Zayed Y, Gakhal I, Dhillon H, Kheiri B, Kerbage J et al (2019) The role of vitamin D supplementation for primary prevention of cancer: meta-analysis of randomized controlled trials. J Community Hosp Internal Med Persp 9:480–488. https://doi.org/10.1080/20009666.2019.1701839CrossRef

14.

Reid IR, Bolland MJ, Grey A (2014) Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 383:146–155. https://doi.org/10.1016/s0140-6736(13)61647-5CrossRefPubMed

15.

Vanhevel J, Verlinden L, Doms S, Wildiers H, Verstuyf A (2022) The role of vitamin D in breast cancer risk and progression. Endocr Relat Cancer 29:R33-r55. https://doi.org/10.1530/erc-21-0182CrossRefPubMed

16.

Kim H, Lipsyc-Sharf M, Zong X, Wang X, Hur J, Song M, Wang M et al (2021) Total vitamin D intake and risks of early-onset colorectal cancer and precursors. Gastroenterology 161:1208-1217.e9. https://doi.org/10.1053/j.gastro.2021.07.002CrossRefPubMed

17.

Kanaan Y, Copeland RL (2022) The link between vitamin D and prostate cancer. Nat Rev Cancer 22:435. https://doi.org/10.1038/s41568-022-00493-yCrossRefPubMed

18.

Jones G (2013) Extrarenal vitamin D activation and interactions between vitamin D₂, vitamin D₃, and vitamin D analogs. Annu Rev Nutr 33:23–44. https://doi.org/10.1146/annurev-nutr-071812-161203CrossRefPubMed

19.

Wilson LR, Tripkovic L, Hart KH, Lanham-New SA (2017) Vitamin D deficiency as a public health issue: using vitamin D2 or vitamin D3 in future fortification strategies. Proc Nutr Soc 76:392–399. https://doi.org/10.1017/s0029665117000349CrossRefPubMed

20.

Holick MF (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362–371. https://doi.org/10.1093/ajcn/79.3.362CrossRefPubMed

21.

Green J (1951) Studies on the analysis of vitamins D. 4. Studies on the irradiation of ergosterol and 7-dehydrocholesterol and the analysis of the products for calciferol, vitamin D3, and component sterols. Biochem J 49:232–243. https://doi.org/10.1042/bj0490232CrossRefPubMedPubMedCentral

22.

Bikle DD (2014) Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 21:319–329. https://doi.org/10.1016/j.chembiol.2013.12.016CrossRefPubMedPubMedCentral

23.

Afzal S, Brøndum-Jacobsen P, Bojesen SE, Nordestgaard BG (2014) Vitamin D concentration, obesity, and risk of diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 2:298–306. https://doi.org/10.1016/s2213-8587(13)70200-6CrossRefPubMed

24.

Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, Cooper JD et al (2013) Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med 10:e1001383. https://doi.org/10.1371/journal.pmed.1001383CrossRefPubMedPubMedCentral

25.

Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000) Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72:690–693. https://doi.org/10.1093/ajcn/72.3.690CrossRefPubMed

26.

Savastano S, Barrea L, Savanelli MC, Nappi F, Di Somma C, Orio F, Colao A (2017) Low vitamin D status and obesity: role of nutritionist. Rev Endocr Metab Disord 18:215–225. https://doi.org/10.1007/s11154-017-9410-7CrossRefPubMed

27.

Fernandes MR, Barreto WDRJ (2017) Association between physical activity and vitamin D: a narrative literature review. Rev Assoc Med Bras (1993) 63:550–556. https://doi.org/10.1590/1806-9282.63.06.550CrossRef

28.

Bicakli DH, Uslu R, Güney SC, Coker A (2020) The relationship between nutritional status, performance status, and survival among pancreatic cancer patients. Nutr Cancer 72:202–208. https://doi.org/10.1080/01635581.2019.1634217CrossRefPubMed

29.

Kubiak J, Kamycheva E, Jorde R (2021) Tracking of serum 25-hydroxyvitamin D during 21 years. Eur J Clin Nutr 75:1069–1076. https://doi.org/10.1038/s41430-020-00814-0CrossRefPubMed

30.

Borel P, Caillaud D, Cano NJ (2015) Vitamin D bioavailability: state of the art. Crit Rev Food Sci Nutr 55:1193–1205. https://doi.org/10.1080/10408398.2012.688897CrossRefPubMed

31.

Stolzenberg-Solomon RZ (2009) Vitamin D and pancreatic cancer. Ann Epidemiol 19:89–95. https://doi.org/10.1016/j.annepidem.2008.03.010CrossRefPubMed

32.

Sanchez GV, Weinstein SJ, Stolzenberg-Solomon RZ (2012) Is dietary fat, vitamin D, or folate associated with pancreatic cancer? Mol Carcinog 51:119–127. https://doi.org/10.1002/mc.20833CrossRefPubMedPubMedCentral

33.

Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC (2010) Ultraviolet B irradiance and vitamin D status are inversely associated with incidence rates of pancreatic cancer worldwide. Pancreas 39:669–674. https://doi.org/10.1097/MPA.0b013e3181ce654dCrossRefPubMed

34.

Bao Y, Ng K, Wolpin BM, Michaud DS, Giovannucci E, Fuchs CS (2010) Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer 102:1422–1427. https://doi.org/10.1038/sj.bjc.6605658CrossRefPubMedPubMedCentral

35.

Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459. https://doi.org/10.1093/jnci/djj101CrossRefPubMed

36.

Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K et al (2016) Prediagnostic plasma 25-hydroxyvitamin D and pancreatic cancer survival. J Clin Oncol 34:2899–2905. https://doi.org/10.1200/jco.2015.66.3005CrossRefPubMedPubMedCentral

37.

Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP et al (2004) Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 25:1015–1026. https://doi.org/10.1093/carcin/bgh086CrossRefPubMed

38.

Pettersson F, Colston KW, Dalgleish AG (2000) Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br J Cancer 83:239–245. https://doi.org/10.1054/bjoc.2000.1281CrossRefPubMedPubMedCentral

39.

Kawa S, Yoshizawa K, Tokoo M, Imai H, Oguchi H, Kiyosawa K, Homma T et al (1996) Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 110:1605–1613. https://doi.org/10.1053/gast.1996.v110.pm8613068CrossRefPubMed

40.

Colston KW, James SY, Ofori-Kuragu EA, Binderup L, Grant AG (1997) Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 76:1017–1020. https://doi.org/10.1038/bjc.1997.501CrossRefPubMedPubMedCentral

41.

van Duijnhoven FJB, Jenab M, Hveem K, Siersema PD, Fedirko V, Duell EJ, Kampman E et al (2018) Circulating concentrations of vitamin D in relation to pancreatic cancer risk in European populations. Int J Cancer 142:1189–1201. https://doi.org/10.1002/ijc.31146CrossRefPubMed

42.

Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, Weinstein SJ et al (2010) Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 172:81–93. https://doi.org/10.1093/aje/kwq120CrossRefPubMedPubMedCentral

43.

Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, Rager H, Virtamo J, Albanes D (2012) Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res 72:1190–1198. https://doi.org/10.1158/0008-5472.Can-11-2950CrossRefPubMedPubMedCentral

44.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D et al (2000) Meta-analysis of observational studies in epidemiology—ā proposal for reporting. Jama-J Am Med Assoc 283:2008–2012. https://doi.org/10.1001/jama.283.15.2008CrossRef

45.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

46.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806–808. https://doi.org/10.1136/bmj.39335.541782.ADCrossRef

47.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

48.

Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D, Calcium (2011) The National Academies Collection: Reports funded by National Institutes of Health. National Academies Press (US) Copyright © 2011, National Academy of Sciences., Washington (DC)

49.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930. https://doi.org/10.1210/jc.2011-0385CrossRefPubMed

50.

Chevalley T, Brandi ML, Cashman KD, Cavalier E, Harvey NC, Maggi S, Cooper C et al (2022) Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clin Exp Res 34:2603–2623. https://doi.org/10.1007/s40520-022-02279-6CrossRefPubMedPubMedCentral

51.

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18–28. https://doi.org/10.1093/ajcn/84.1.18CrossRefPubMed

52.

DerSimonian R, Laird N (2015) Meta-analysis in clinical trials revisited. Contemp Clin Trials 45:139–145. https://doi.org/10.1016/j.cct.2015.09.002CrossRefPubMedPubMedCentral

53.

DerSimonian R (1996) Meta-analysis in the design and monitoring of clinical trials. Stat Med 15:1237–48. https://doi.org/10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-NCrossRefPubMed

54.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. https://doi.org/10.1016/0197-2456(86)90046-2CrossRefPubMed

55.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRefPubMedPubMedCentral

56.

Jeon SM, Shin EA (2018) Exploring vitamin D metabolism and function in cancer. Exp Mol Med 50:1–14. https://doi.org/10.1038/s12276-018-0038-9CrossRefPubMed

57.

Marigoudar JB, Sarkar D, Yuguda YM, Abutayeh RF, Kaur A, Pati A, Mitra D et al (2022) Role of vitamin D in targeting cancer and cancer stem cell populations and its therapeutic implications. Med Oncol 40:2. https://doi.org/10.1007/s12032-022-01855-0CrossRefPubMed

58.

Chiang KC, Chen TC (2009) Vitamin D for the prevention and treatment of pancreatic cancer. World J Gastroenterol 15:3349–3354. https://doi.org/10.3748/wjg.15.3349CrossRefPubMedPubMedCentral

59.

Mondul AM, Weinstein SJ, Layne TM, Albanes D (2017) Vitamin D and cancer risk and mortality: state of the science, gaps, and challenges. Epidemiol Rev 39:28–48. https://doi.org/10.1093/epirev/mxx005CrossRefPubMedCentral

60.

Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ et al (2013) Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 105:1027–1035. https://doi.org/10.1093/jnci/djt123CrossRefPubMedPubMedCentral

61.

Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A (2010) 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring) 18:1906–1910. https://doi.org/10.1038/oby.2010.11CrossRefPubMed

62.

Vaidya A, Williams JS, Forman JP (2012) The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: the NHS and the HPFS. Obesity (Silver Spring) 20:186–191. https://doi.org/10.1038/oby.2011.210CrossRefPubMed

63.

Earthman CP, Beckman LM, Masodkar K, Sibley SD (2012) The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond) 36:387–396. https://doi.org/10.1038/ijo.2011.119CrossRefPubMed

64.

McPhail S, Johnson S, Greenberg D, Peake M, Rous B (2015) Stage at diagnosis and early mortality from cancer in England. Br J Cancer 112(Suppl 1):S108–S115. https://doi.org/10.1038/bjc.2015.49CrossRefPubMedPubMedCentral

65.

Zwaigenbaum L, Stone W (2008) Early detection. Autism 12:427–432. https://doi.org/10.1177/1362361308097836CrossRefPubMed

66.

Fernández-Lázaro D, Seco-Calvo J (2023) Nutrition, nutritional status and functionality. Nutrients. https://doi.org/10.3390/nu15081944CrossRefPubMedPubMedCentral

67.

Zhang X, Chen Y, Jin S, Bi X, Chen D, Zhang D, Liu L et al (2020) Association of serum 25-Hydroxyvitamin D with Vitamin D intervention and outdoor activity among children in North China: an observational study. BMC Pediatr 20:542. https://doi.org/10.1186/s12887-020-02435-9CrossRefPubMedPubMedCentral

68.

Holick MF (2017) The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 18:153–165. https://doi.org/10.1007/s11154-017-9424-1CrossRefPubMed

69.

Weinstein SJ, Mondul AM, Yu K, Layne TM, Abnet CC, Freedman ND, Stolzenberg-Solomon RZ et al (2018) Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival. Eur J Epidemiol 33:1087–1099. https://doi.org/10.1007/s10654-018-0428-2CrossRefPubMedPubMedCentral

70.

Rasmussen LS, Yilmaz MK, Falkmer UG, Poulsen L, Bøgsted M, Christensen HS, Bojesen SE et al (2021) Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. Eur J Cancer 144:72–80. https://doi.org/10.1016/j.ejca.2020.10.038CrossRefPubMed

71.

Haas M, Kern C, Kruger S, Michl M, Modest DP, Giessen C, Schulz C et al (2015) Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21–1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. Tumour Biol 36:2631–2640. https://doi.org/10.1007/s13277-014-2885-xCrossRefPubMed

72.

McGovern EM, Lewis ME, Niesley ML, Huynh N, Hoag JB (2016) Retrospective analysis of the influence of 25-hydroxyvitamin D on disease progression and survival in pancreatic cancer. Nutr J 15:17. https://doi.org/10.1186/s12937-016-0135-3CrossRefPubMedPubMedCentral

73.

LeFevre ML (2015) Screening for vitamin D deficiency in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 162:133–140. https://doi.org/10.7326/m14-2450CrossRefPubMed

74.

Kantor ED, Rehm CD, Du M, White E, Giovannucci EL (2016) Trends in dietary supplement use among US adults from 1999–2012. JAMA 316:1464–1474. https://doi.org/10.1001/jama.2016.14403CrossRefPubMedPubMedCentral

75.

Adams JS, Hewison M (2012) Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 523:95–102. https://doi.org/10.1016/j.abb.2012.02.016CrossRefPubMedPubMedCentral

76.

Zugmaier G, Jager R, Grage B, Gottardis MM, Havemann K, Knabbe C (1996) Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 73:1341–1346. https://doi.org/10.1038/bjc.1996.256CrossRefPubMedPubMedCentral

77.

Schwartz GG, Eads D, Naczki C, Northrup S, Chen T, Koumenis C (2008) 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther 7:430–436. https://doi.org/10.4161/cbt.7.3.5418CrossRefPubMed

78.

Albrechtsson E, Jonsson T, Möller S, Höglund M, Ohlsson B, Axelson J (2003) Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number. Pancreatology 3:41–46. https://doi.org/10.1159/000069149CrossRefPubMed

79.

Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89:5387–5391. https://doi.org/10.1210/jc.2004-0360CrossRefPubMed

80.

Skinner HG (2008) Vitamin D for the treatment and prevention of pancreatic cancer. Cancer Biol Ther 7:437–439. https://doi.org/10.4161/cbt.7.3.5585CrossRefPubMed

81.

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA et al (2014) Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159:80–93. https://doi.org/10.1016/j.cell.2014.08.007CrossRefPubMedPubMedCentral

82.

Hennig R, Ding XZ, Adrian TE (2004) On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol 19:999–1011. https://doi.org/10.14670/hh-19.999

83.

Bear AS, Vonderheide RH, O’Hara MH (2020) Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 38:788–802. https://doi.org/10.1016/j.ccell.2020.08.004CrossRefPubMedPubMedCentral

84.

Maestro B, Molero S, Bajo S, Dávila N, Calle C (2002) Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct 20:227–232. https://doi.org/10.1002/cbf.951CrossRefPubMed

85.

Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC (1983) 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221:1181–1183. https://doi.org/10.1126/science.6310748CrossRefPubMed

86.

Lemire JM, Adams JS, Sakai R, Jordan SC (1984) 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 74:657–661. https://doi.org/10.1172/jci111465CrossRefPubMedPubMedCentral

87.

Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE (2007) Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647. https://doi.org/10.4049/jimmunol.179.3.1634CrossRefPubMed

88.

Mahon BD, Wittke A, Weaver V, Cantorna MT (2003) The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89:922–932. https://doi.org/10.1002/jcb.10580CrossRefPubMed

89.

Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C (2010) Vitamin D: modulator of the immune system. Curr Opin Pharmacol 10:482–496. https://doi.org/10.1016/j.coph.2010.04.001CrossRefPubMed

90.

Mora JR, Iwata M, von Andrian UH (2008) Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 8:685–698. https://doi.org/10.1038/nri2378CrossRefPubMedPubMedCentral

91.

Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC (1985) 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 134:3032–3035CrossRefPubMed

92.

Schlingmann KP (2021) Vitamin D-dependent Hypercalcemia. Endocrinol Metab Clin North Am 50:729–742. https://doi.org/10.1016/j.ecl.2021.08.005CrossRefPubMed

93.

Tebben PJ, Singh RJ, Kumar R (2016) Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr Rev 37:521–547. https://doi.org/10.1210/er.2016-1070CrossRefPubMedPubMedCentral

94.

Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S et al (2009) Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice–the ECHO observational study. Nephrol Dial Transpl 24:2852–2859. https://doi.org/10.1093/ndt/gfp144CrossRef

95.

Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ et al (2006) Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70:351–357. https://doi.org/10.1038/sj.ki.5001542CrossRefPubMed

Title: The association between circulating 25-hydroxyvitamin D and pancreatic cancer: a systematic review and meta-analysis of observational studies
Authors: Yajing Shen
Junfen Xia
Chuncheng Yi
Tiandong Li
Peng Wang
Liping Dai
Jianxiang Shi
Keyan Wang
Changqing Sun
Hua Ye
Publication date: 03-01-2024
Publisher: Springer Berlin Heidelberg
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: European Journal of Nutrition / Issue 3/2024
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-023-03302-w

Optimal vitamin D supplement dosage for improving insulin resistance in children and adolescents with overweight/obesity: a systematic review and network meta-analysis

Open Access
Overweight
Original Contribution

Pre-prandial plasma liver-expressed antimicrobial peptide 2 (LEAP2) concentration in humans is inversely associated with hunger sensation in a ghrelin independent manner

Obesity
Original Contribution

Associations of dietary choline and betaine with all-cause mortality: a prospective study in a large Swedish cohort

Open Access
Original Contribution

Association of plant-based diets with total and cause-specific mortality across socioeconomic deprivation level: a large prospective cohort

Original Contribution

Post-prandial muscle protein synthesis rates following the ingestion of pea-derived protein do not differ from ingesting an equivalent amount of milk-derived protein in healthy, young males

Open Access
Original Contribution

Weight regain, but not weight loss exacerbates hepatic fibrosis during multiple weight cycling events in male mice

Metabolic Dysfunction-Associated Steatotic Liver Disease
Original Contribution

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on adolescent vaping

Pediatrics
On-demand webinar

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content